Cargando…

Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis

The safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors in elderly patients with diabetic kidney disease (DKD) is still controversial. This study aimed to analyze the safety of SGLT2 inhibitors in elderly patients with type 2 diabetes mellitus (T2DM) and DKD. We systematically searched PubM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yi, An, Chuan, Liu, Peilong, Yang, Fan, Zhao, Quanlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	State-of-the-Art Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228313/ https://www.ncbi.nlm.nih.gov/pubmed/37246403 http://dx.doi.org/10.1080/0886022X.2023.2217287

Ejemplares similares

Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
por: Oh, Jaewon, et al.
Publicado: (2021)

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
por: Lopaschuk, Gary D., et al.
Publicado: (2020)

Immunometabolism in type 2 diabetes mellitus: tissue-specific interactions
por: Pinheiro-Machado, Erika, et al.
Publicado: (2020)

Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
por: Kubota, Yoshiaki, et al.
Publicado: (2022)

The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
por: Guardado-Mendoza, Rodolfo, et al.
Publicado: (2013)

Tuberculosis and diabetes mellitus – an underappreciated association
por: Skowroński, Marcin, et al.
Publicado: (2014)

The COVID-19 pandemic and diabetes mellitus
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2020)

Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes
por: Packer, Milton, et al.
Publicado: (2023)

Influence of lifestyle on the course of type 1 diabetes mellitus
por: Piłaciński, Stanisław, et al.
Publicado: (2014)

Pioglitazone in diabetic kidney disease: forgotten but not gone
por: Papaetis, Georgios S.
Publicado: (2022)

Micro-ribonucleic acid modulation with oxidative stress and inflammation in patients with type 2 diabetes mellitus – a review article
por: Klisic, Aleksandra, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?
por: Mitrovic, Bojan, et al.
Publicado: (2022)

Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
por: Cice, Gennaro, et al.
Publicado: (2022)

Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention
por: Ma, Xiaoju, et al.
Publicado: (2023)

Biomarker for early renal microvascular and diabetic kidney diseases
por: Futrakul, Narisa, et al.
Publicado: (2017)

Dietary and nutraceutical approach to type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2014)

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
por: Michos, Erin D., et al.
Publicado: (2023)

Novel methods of continuous glucose monitoring and telehealth in the improvement of diabetes care: a narrative review
por: Hohendorff, Jerzy, et al.
Publicado: (2021)

Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update
por: Ying, Qidi, et al.
Publicado: (2017)

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options
por: Jankowski, Joachim, et al.
Publicado: (2021)

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
por: Desai, Mehul, et al.
Publicado: (2017)

Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns
por: Papaetis, Georgios S., et al.
Publicado: (2015)

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
por: Packer, Milton
Publicado: (2022)

Trauma-informed care in the newborn intensive care unit: promoting safety, security and connectedness
por: Sanders, M R, et al.
Publicado: (2018)

Is miRNA-375 a promising biomarker for early detection and monitoring of patients with type 2 diabetes?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus
por: Bays, Harold
Publicado: (2013)

A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials
por: Selker, H P, et al.
Publicado: (2014)

An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease
por: Zhao, Hanxue, et al.
Publicado: (2023)

Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury
por: DeFilippis, Andrew P., et al.
Publicado: (2019)

A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients
por: Zuo, Qianwei, et al.
Publicado: (2022)

Diabetes and dementia – the two faces of Janus
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2020)

Update on prevention of diabetic foot ulcer
por: Miranda, Cesare, et al.
Publicado: (2021)

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Kumar, Surender, et al.
Publicado: (2019)

A meta-analysis of the association between diabetic patients and AVF failure in dialysis
por: Yan, Yan, et al.
Publicado: (2018)

Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
por: Tatsumi, Tomoaki, et al.
Publicado: (2022)

APOE gene polymorphisms and diabetic peripheral neuropathy
por: Monastiriotis, Christodoulos, et al.
Publicado: (2012)

Telemedicine and diabetes during the COVID-19 era
por: Papazafiropoulou, Athanasia
Publicado: (2022)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
por: Roberts, AW, et al.
Publicado: (2016)

Anti-SARS-CoV-2 vaccine-induced myocarditis – real but, in general, rare and mild: A consensus statement from the Studies Committee of the Portuguese Society of Cardiology
por: Sousa, José Pedro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_slts5g9f2du9tulia3nk3pk96b